Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C19H21FN2O2.C4H4O4 |
Molecular Weight | 772.8334 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 5 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)C2=C(F)C=CC=C2.CN(C)CCO\N=C(\C=C\C3=CC=C(O)C=C3)C4=C(F)C=CC=C4
InChI
InChIKey=RNLKLYQQDLHHBH-ABDBJYMXSA-N
InChI=1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
Eplivanserin (SR 46349) is an antagonist of serotonin 2A receptor. Eplivanserin was previously in development by Sanofi-aventis in an effort to educate the public regarding this new mechanism of action for sleep aids. Eplivanserin was reviewed by the FDA as a potential treatment for patients with chronic insomnia, but the FDA requested additional information regarding benefit-risk and development of the drug has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00253968
Phase III study: 5 mg/day for 12 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB30302
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL257704
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
WW-97
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
BT8UYC46KA
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
130580-02-8
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
DTXSID201033898
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
135456189
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
C95215
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY | |||
|
100000092728
Created by
admin on Fri Dec 15 15:41:52 GMT 2023 , Edited by admin on Fri Dec 15 15:41:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD